NCT04834115

Efficacy of Ivermectin in Outpatients With Non-severe COVID-19

Efficacy of Ivermectin in Outpatients With Non-severe COVID-19: A Randomized Controlled Trial

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 400 (estimated)
• Sponsor: Universidad Nacional de Asunción · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a randomized controlled trial to evaluate the efficacy of ivermectin in reducing the risk of progression to severe disease and hospitalizations in COVID-19 patients.

Detailed description

This is a randomized controlled trial to evaluate the efficacy of ivermectin in COVID-19 outpatients reducing the risk of progression to severe disease. Patients with COVID-19 infection are randomized to receive a single dose of 200mcg/kg of ivermectin or a placebo. The randomization code is generated by the trial statistician. The allocation is made after fulfilment of both inclusion and exclusion criteria.

Conditions

• Covid19
• Coronavirus Infection

Interventions

Type	Name	Description
DRUG	Ivermectin Tablets	Oral ivermectin at a one time dose
OTHER	Placebo	Oral placebo at a one time dose

Timeline

• Start date: 2020-11-17
• Primary completion: 2021-04-30
• Completion: 2021-05-30
• First posted: 2021-04-06
• Last updated: 2021-04-06

Locations

1 site across 1 country: Paraguay